FDA gives tentative nod to Zydus Cadila’s generic Vimpat
The Food and Drug Administration has given a tentative OK for Zydus Cadila’s generic Vimpat (lacosamide tablets). The tentative approval includes the 50-mg, 100-mg, 150-mg and 200-mg dosage strengths of the product.
Lacosamide is an antiepileptic drug used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain.
The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, Zydus said.
No comments found